- Point-of-care biopsy solutions, which allow for immediate tissue sampling and diagnostic analysis at or near the site of patient care, are becoming increasingly vital in modern clinical workflows due to their ability to provide rapid results, reduce patient anxiety, and enable timely treatment decisions in both hospital and outpatient settings
- The escalating demand for point-of-care biopsy is primarily fueled by the rising global incidence of cancer, increasing emphasis on early diagnosis, and technological advancements in portable, minimally invasive biopsy devices
- North America dominates the point-of-care biopsy market with the largest revenue share of 43.4% in 2024, characterized by advanced healthcare infrastructure, high healthcare spending, and a strong presence of leading medical device manufacturers
- Asia-Pacific is expected to be the fastest growing region in the point-of-care biopsy market during the forecast period, with a CAGR of 15.4%, due to increasing cancer awareness, expanding healthcare access in rural areas, and rising disposable incomes, particularly in countries such as China, India, and Japan
- Reagents and kits segment dominates the point-of-care biopsy market with a market share of 61.3% in 2024, driven by their extensive and recurring need for performing diagnostic tests, supporting diverse applications in oncology, infectious diseases, and genetic diagnostics
